Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456911 | 1.00 | KDM4E (0.55) | KDM4EGAAS1PR4S1PR3GPR139 | |
| SCHEMBL4450260 | 0.89 | NPC1 (0.47) | LMNANPC1ALDH1A1 | |
| SCHEMBL4450252 | 0.89 | NPC1 (0.47) | LMNANPC1ALDH1A1 | |
| SCHEMBL4448201 | 0.88 | GPR139 (0.50) | KDM4EGAAS1PR3GPR139ALDH1A1 | |
| SCHEMBL4448205 | 0.88 | GPR139 (0.50) | KDM4EGAAS1PR3GPR139ALDH1A1 | |
| SCHEMBL4445032 | 0.87 | HPGDS (0.59) | GAALMNANPC1ALDH1A1 | |
| SCHEMBL4445027 | 0.87 | HPGDS (0.59) | GAALMNANPC1ALDH1A1 | |
| SCHEMBL4456906 | 0.86 | KMT2A (0.49) | LMNATP53NPC1ALDH1A1 | |
| SCHEMBL4456908 | 0.86 | KMT2A (0.49) | LMNATP53NPC1ALDH1A1 | |
| SCHEMBL4448522 | 0.85 | L3MBTL1 (0.54) | LMNANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | NEUROMED PHRAMACEUTICALS LTD. (CA) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012010-A1 | Amino acid derivatives as calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | KDM4E 3941/4885GAA 966/4885S1PR4 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.